Above we demonstrated that the IL13 signaling pathway is activated in LECs of people with NASH (Figure 3) and increased IL13 gene and protein expression in vitro when LECs were treated with oxLDL (Figures 5D–F). The gene discussed is IL13; the disease is metabolic dysfunction-associated steatohepatitis.